"60" . "Ren\u00E1ln\u00ED denervace u pacient\u016F s rezistentn\u00ED hypertenz\u00ED: je mo\u017En\u00E9 ji je\u0161t\u011B resuscitovat?"@cs . . . "Ren\u00E1ln\u00ED denervace u pacient\u016F s rezistentn\u00ED hypertenz\u00ED: je mo\u017En\u00E9 ji je\u0161t\u011B resuscitovat?"@cs . . "Renal denervation in patients with resistant hypertension: is it still possible to resuscitate?"@en . "Je jen m\u00E1lo oblast\u00ED ve vnit\u0159n\u00EDm l\u00E9ka\u0159stv\u00ED, kter\u00E9 zaznamenaly extr\u00E9mn\u011B rychl\u00FD rozmach a implementaci do klinick\u00E9 praxe v posledn\u00EDch 5 letech, jako je katetriza\u010Dn\u00ED ren\u00E1ln\u00ED denervace (RDN) u pacient\u016F nejen s rezistentn\u00ED hypertenz\u00ED. Z\u00E1kladn\u00EDm probl\u00E9mem, kter\u00FD nebyl dostate\u010Dn\u011B \u0159e\u0161en ve v\u0161ech studi\u00EDch s RDN, je skute\u010Dnost, \u017Ee v\u00EDce ne\u017E 50% pacient\u016F s tzv. resistentn\u00ED hypertenz\u00ED jsou ve skute\u010Dnosti nemocn\u00ED neuk\u00E1zn\u011Bn\u00ED a neadheruj\u00EDc\u00ED k zaveden\u00E9 mediaci. V\u00FDsledky studie SYMPLICITY HTN-3 neprok\u00E1zaly \u017E\u00E1dn\u00E9 rozd\u00EDly mezi zm\u011Bnou krevn\u00EDho tlaku u pacient\u016F s provedenou RDN proti skupin\u011B s tzv. fale\u0161nou procedurou, tedy pokra\u010Duj\u00EDc\u00ED medikament\u00F3zn\u00ED terapii. Budoucnost RDN je v\u00EDce ne\u017E otazn\u00E1 a je pot\u0159eba vr\u00E1tit se zp\u011Bt k anim\u00E1ln\u00EDm studi\u00EDm, kter\u00E9 ov\u011B\u0159\u00ED re\u00E1lnou efektivitu RDN redefinovat populaci pacient\u016F indikovan\u00FDch k RDN a ov\u011B\u0159it pou\u017Eitelnost nov\u011B vyvinut\u00FDch technologi\u00ED."@cs . . "resistant hypertension; renal sympathetic innervation; renal denervation"@en . "Ren\u00E1ln\u00ED denervace u pacient\u016F s rezistentn\u00ED hypertenz\u00ED: je mo\u017En\u00E9 ji je\u0161t\u011B resuscitovat?" . "[F3F82B50F026]" . . "15110" . . . . "I" . . "0042-773X" . "Renal denervation in patients with resistant hypertension: is it still possible to resuscitate?"@en . "T\u00E1borsk\u00FD, Milo\u0161" . "Ren\u00E1ln\u00ED denervace u pacient\u016F s rezistentn\u00ED hypertenz\u00ED: je mo\u017En\u00E9 ji je\u0161t\u011B resuscitovat?" . "CZ - \u010Cesk\u00E1 republika" . . . . . "Je jen m\u00E1lo oblast\u00ED ve vnit\u0159n\u00EDm l\u00E9ka\u0159stv\u00ED, kter\u00E9 zaznamenaly extr\u00E9mn\u011B rychl\u00FD rozmach a implementaci do klinick\u00E9 praxe v posledn\u00EDch 5 letech, jako je katetriza\u010Dn\u00ED ren\u00E1ln\u00ED denervace (RDN) u pacient\u016F nejen s rezistentn\u00ED hypertenz\u00ED. Z\u00E1kladn\u00EDm probl\u00E9mem, kter\u00FD nebyl dostate\u010Dn\u011B \u0159e\u0161en ve v\u0161ech studi\u00EDch s RDN, je skute\u010Dnost, \u017Ee v\u00EDce ne\u017E 50% pacient\u016F s tzv. resistentn\u00ED hypertenz\u00ED jsou ve skute\u010Dnosti nemocn\u00ED neuk\u00E1zn\u011Bn\u00ED a neadheruj\u00EDc\u00ED k zaveden\u00E9 mediaci. V\u00FDsledky studie SYMPLICITY HTN-3 neprok\u00E1zaly \u017E\u00E1dn\u00E9 rozd\u00EDly mezi zm\u011Bnou krevn\u00EDho tlaku u pacient\u016F s provedenou RDN proti skupin\u011B s tzv. fale\u0161nou procedurou, tedy pokra\u010Duj\u00EDc\u00ED medikament\u00F3zn\u00ED terapii. Budoucnost RDN je v\u00EDce ne\u017E otazn\u00E1 a je pot\u0159eba vr\u00E1tit se zp\u011Bt k anim\u00E1ln\u00EDm studi\u00EDm, kter\u00E9 ov\u011B\u0159\u00ED re\u00E1lnou efektivitu RDN redefinovat populaci pacient\u016F indikovan\u00FDch k RDN a ov\u011B\u0159it pou\u017Eitelnost nov\u011B vyvinut\u00FDch technologi\u00ED." . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . "12" . "2"^^ . "1"^^ . "RIV/61989592:15110/14:33151899!RIV15-MSM-15110___" . "Transcatheter renal denervation (RDN) has been markedly applied and developer in clinical practice in past five years and not only for patients with resistant hypertension. The issue that more than 50% patients with so-called resistant hypertension. The issue that more than 50% patients with so-called resistant hypertension are in fact patients without adherence to this type of medication has not been resolved in RDN trials till now. The study Symplicity HTN-3 showed no differences in blood pressure change between the patients with RDN and group of patients after false procedure who continued in their drug therapy. Future of RDN is more than questionable and there is a need to return to animal studies that will verify the real effectiveness of RDN, subsequently, will redefine population of patients indicated for RDN and confirm the applicability of newly developer techniques."@en . . "Schejbalov\u00E1, Marcela" . "5"^^ . "RIV/61989592:15110/14:33151899" . "42174" .